22-28687948-G-A
Variant summary
Our verdict is Benign. Variant got -13 ACMG points: 0P and 13B. BP4_StrongBP6_Very_StrongBP7
The NM_007194.4(CHEK2):c.1581C>T(p.Ala527Ala) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000182 in 1,596,220 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Consequence
NM_007194.4 synonymous
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -13 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152138Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000385 AC: 9AN: 233604Hom.: 0 AF XY: 0.0000468 AC XY: 6AN XY: 128324
GnomAD4 exome AF: 0.0000173 AC: 25AN: 1444082Hom.: 0 Cov.: 30 AF XY: 0.0000167 AC XY: 12AN XY: 718782
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152138Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74310
ClinVar
Submissions by phenotype
not specified Benign:2
Variant summary: CHEK2 c.1581C>T alters a non-conserved nucleotide resulting in a synonymous change. 5/5 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 4.2e-05 in 260066 control chromosomes. This frequency is not higher than expected for a pathogenic variant in CHEK2 causing Breast Cancer (4.2e-05 vs 0.00031), allowing no conclusion about variant significance. To our knowledge, no occurrence of c.1581C>T in individuals affected with Breast Cancer and no experimental evidence demonstrating its impact on protein function have been reported. One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation and classified the variant as likely benign. In addition, Tavor_2011 reports the variant as "Polymorphism" identified in pt with non-Hodgkins lymphoma. Based on the evidence outlined above, the variant was classified as likely benign. -
- -
Hereditary cancer-predisposing syndrome Benign:2
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
- -
Familial cancer of breast Benign:2
- -
This variant is considered benign. This variant is a silent/synonymous amino acid change and it is not expected to impact splicing. -
Li-Fraumeni syndrome 2 Benign:1
- -
not provided Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at